[go: up one dir, main page]

FI951702L - Farmaseuttinen menetelmä osteoporoosin hoitamiseksi - Google Patents

Farmaseuttinen menetelmä osteoporoosin hoitamiseksi Download PDF

Info

Publication number
FI951702L
FI951702L FI951702A FI951702A FI951702L FI 951702 L FI951702 L FI 951702L FI 951702 A FI951702 A FI 951702A FI 951702 A FI951702 A FI 951702A FI 951702 L FI951702 L FI 951702L
Authority
FI
Finland
Prior art keywords
treating osteoporosis
pharmaceutical method
pharmaceutical
osteoporosis
treating
Prior art date
Application number
FI951702A
Other languages
English (en)
Swedish (sv)
Other versions
FI951702A0 (fi
FI951702A7 (fi
Inventor
Hiroyasu Tobe
Kazuyuki Kitamura
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of FI951702A0 publication Critical patent/FI951702A0/fi
Publication of FI951702L publication Critical patent/FI951702L/fi
Publication of FI951702A7 publication Critical patent/FI951702A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FI951702A 1994-04-12 1995-04-10 Farmaseuttinen menetelmä osteoporoosin hoitamiseksi FI951702A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7323094 1994-04-12

Publications (3)

Publication Number Publication Date
FI951702A0 FI951702A0 (fi) 1995-04-10
FI951702L true FI951702L (fi) 1995-10-13
FI951702A7 FI951702A7 (fi) 1995-10-13

Family

ID=13512179

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951702A FI951702A7 (fi) 1994-04-12 1995-04-10 Farmaseuttinen menetelmä osteoporoosin hoitamiseksi

Country Status (13)

Country Link
US (1) US5604263A (fi)
EP (1) EP0677289B1 (fi)
KR (1) KR950031059A (fi)
AT (1) ATE175575T1 (fi)
AU (1) AU696334B2 (fi)
CA (1) CA2146820A1 (fi)
DE (1) DE69507185T2 (fi)
DK (1) DK0677289T3 (fi)
ES (1) ES2129691T3 (fi)
FI (1) FI951702A7 (fi)
HU (1) HUT71604A (fi)
NO (1) NO951422L (fi)
TW (1) TW427901B (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20090263522A1 (en) * 2001-10-26 2009-10-22 Babish John G Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
JPWO2003068205A1 (ja) * 2002-02-14 2005-06-02 麒麟麦酒株式会社 肥満治療剤および肥満防止または改善用食品
NZ539642A (en) * 2002-10-21 2007-01-26 Metaproteomics Llc Compositions containing extracts from hops in combination with a second component for treating inflammatory response
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
ATE421357T1 (de) * 2003-05-22 2009-02-15 Metaproteomics Llc Entzündungshemmende arzneizubereitungen zur entzündungsverminderung und die therapie oder die prophylaxe von der gastrischen toxizität
US20050192356A1 (en) 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
EP2248532A1 (en) * 2005-08-09 2010-11-10 Metaproteomics, LLP Protein kinase modulation by hops and acacia products cross-reference to related applications
WO2007067812A2 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
WO2007149503A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc. Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
CN101711161A (zh) * 2007-03-19 2010-05-19 麦特普罗泰欧米克斯有限公司 促进骨骼和关节健康的方法及组合物
AU2008251756B2 (en) 2007-05-11 2013-06-06 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
EP2229178A4 (en) * 2007-12-10 2011-03-09 Metaproteomics Llc 1,3-CYCLOPENTADIONE MODULATORS SUBSTITUTED WITH MULTI-TARGETED PROTEIN KINASES FOR CANCER, ANGIOGENESIS AND INFLAMMATORY TRACT ASSOCIATED THERETO
WO2009124176A1 (en) * 2008-04-02 2009-10-08 Metaprotemics, Llc Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
US11801225B2 (en) * 2018-02-16 2023-10-31 The New Zealand Institute For Plant And Food Research Limited Oral dosage forms comprising a hops extract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892808A (en) * 1965-11-17 1975-07-01 Carlton & United Breweries Hop extracts
DE1901277A1 (de) * 1969-01-10 1970-08-06 Partipharm Ag Mittel zur Kompensation uebermaessigen Zigarettenkonsums
US5370863A (en) * 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
JPH06312924A (ja) * 1993-04-28 1994-11-08 Asahi Breweries Ltd 抗酸化作用を有するフムロン類の利用

Also Published As

Publication number Publication date
EP0677289A3 (en) 1996-10-23
EP0677289B1 (en) 1999-01-13
NO951422D0 (no) 1995-04-11
HU9501043D0 (en) 1995-06-28
FI951702A0 (fi) 1995-04-10
ES2129691T3 (es) 1999-06-16
US5604263A (en) 1997-02-18
CA2146820A1 (en) 1995-10-13
EP0677289A2 (en) 1995-10-18
AU1638495A (en) 1995-10-19
DK0677289T3 (da) 1999-09-06
HUT71604A (en) 1996-01-29
TW427901B (en) 2001-04-01
DE69507185D1 (de) 1999-02-25
NO951422L (no) 1995-10-13
AU696334B2 (en) 1998-09-10
FI951702A7 (fi) 1995-10-13
ATE175575T1 (de) 1999-01-15
DE69507185T2 (de) 1999-09-09
KR950031059A (ko) 1995-12-18

Similar Documents

Publication Publication Date Title
FI951702L (fi) Farmaseuttinen menetelmä osteoporoosin hoitamiseksi
FI952996L (fi) Jätteen käsittelymenetelmä
FI971568A7 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
IS4812A (is) Samsett meðferð fyrir beingisnun
FI960281A7 (fi) Menetelmä tuotteiden sterilisoimiseksi
NO950275D0 (no) Kombinasjonsbehandling for osteoporose
SG50018A1 (en) Method for developing treatment
FI951856A7 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
FI962069L (fi) Menetelmä karpolaktaamin valmistamiseksi
FI954423L (fi) Menetelmä taksoidien puhdistamiseksi
FI954119A0 (fi) Menetelmä kiinteän jätteen käsittelemiseksi
KR970001365A (ko) 알킬하이드로겐클로로실란의 제조방법
FI20050181L (fi) Menetelmä valmistaa 21-kloorikortikosteroideja
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
FI951903L (fi) Menetelmä gingkolidi B:n valmistamiseksi ginkgolidi C:stä
FI955800L (fi) Menetelmä aminoalkyyliganidiinien valmistamiseksi
BR9502171A (pt) Sistema de lastro para máquina de compactação
FI973173L (fi) Menetelmä kondensaatin käsittelemiseksi
DE69500952D1 (de) Solebehandlungsmethode
FI963018A7 (fi) Menetelmä gammapyronien valmistamiseksi
ID16924A (id) Metode perlakuan poliolefin
FI971675A7 (fi) Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi
BR9711676A (pt) M-todo de tratamento de doen-asd pÄs-menop usicas incluindo osteoporose
EE200000074A (et) Meetod ja seade jäätmete töötlemiseks
FI972383A0 (fi) Osteoporoosihoitojaksoon tarkoitettu pakkaus